
|Peer-Reviewed|December 24, 2020
- February 2021
- Volume 27
- Issue 2
Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Advertisement
Articles in this issue
almost 5 years ago
Radiation Oncology’s Role in the Next Chapter of Payment Reformalmost 5 years ago
Flying the Plane While You Build Italmost 5 years ago
The Untapped Potential of Cell and Gene Therapyalmost 5 years ago
Possible Treatment Identified for Aggressive NSCLC SubsetNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
3
Pirtobrutinib Outperforms Bendamustine-Rituximab in Frontline CLL/SLL
4
In CLL, New Therapies Offer Potential for Personalized Approaches
5









































